Application No.: Not yet available

Preliminary Amendment

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) An isolated receptor which binds glial cell lined-derived neurotrophic factor (GDNF), said receptor comprising at least one polypeptide having a molecular weight selected from the group consisting of polypeptides of about 55 kD, 70kD, 135kD, and 300kD molecular weight, as determined by SDS-PAGE on 4-20% gradient gels.

- 2. (Original) A competitive assay for identifying compounds which bind to GDNF receptors comprising
- a) incubating said compounds with cells which express c-RET receptors in the presence of an excess of labeled GDNF;
 - b) measuring the amount of labeled GDNF bound to said cells; and
- c) comparing amount labeled GDNF bound to said cells to that of controls not incubated with said compounds.
- 3. (Original) The method of claim 2 wherein the cells are selected from the group consisting of NB2/a, MN-1, and PC12 cells.
 - 4. (Original) The method of claim 2 wherein the labeled GDNF is ¹²⁵1-GDNF.
- 5. (Original) A competitive assay for identifying compounds which bind to isolated GDNF receptors comprising
- a) incubating said compounds with isolated c-RET receptors in the presence of an excess of labeled GDNF;
 - b) measuring the amount of labeled GDNF bound to said receptors; and
- c) comparing amount labeled GDNF bound to said receptors to that of controls not incubated with said compounds.

Application No.: Not yet available

Preliminary Amendment

6. (Original) The method of claim 5 wherein the receptors are polypeptides which bind GDNF selected from the group consisting of polypeptides about 55kD, 70kD, 135kD, 155kD, and 300kD molecular weight.

- 7. (Original) The method of claim 6 wherein the polypeptide is about 155kD molecular weight.
 - 8. (Original) The method of claim 5 wherein the isolated receptor is c-RET.
 - 9. (Original) The method of claim 5 wherein the labeled GDNF is ¹²⁵1-GDNF.
 - 10. (Canceled)
 - 11. (Canceled)
- 12. (Original) A method for identifying compounds which are GDNF homologs comprising
- a) incubating said compounds with cells which express c-RET receptors; and
- b) determining whether said compounds effect an increase in c-fos mRNA levels.
- 13. (Original) The method of claim 12 wherein said cells are selected from the group consisting of PC12, MN-1, and NB2/a.
- 14. (Original) A method for identifying compounds which are GDNF homologs comprising
- a) incubating said compounds with cells which express c-RET receptors under non-permissive conditions for said cells; and
- b) determining the number of surviving cells as compared to controls not incubated with said compounds.

Applicati n No.: Not yet available

Preliminary Amendment

15. (Original) The method of claim 14 wherein said cells are selected from the

group consisting of PC12, MN-1, and NB2/a.

16. (Original) A method for identifying compounds which are GDNF analogs

comprising

a) incubating said compounds with cells which express c-RET receptors

in the presence of concentrations of GDNF effective for phosphorylating tyrosine; and

determining whether said compounds effect a decrease in the tyrosine

phosphorylation as compared with controls not incubated with said compounds.

17. (Original) The method of claim 16 wherein said cells are selected from the

group consisting of PC12, MN-1, and NB2/a.

18. (Original) A method for identifying compounds which are GDNF analogs

comprising

a) incubating said compounds with cells which express c-RET receptors

in the presence of concentrations of GDNF effective for increasing c-fos mRNA levels; and

b) determining whether said compounds effect a decrease in c-fos mRNA

levels as compared with controls not incubated with said compounds.

19. (Original) The method of claim 18 wherein said cells are selected from the

group consisting of PC12, MN-1, and NB2/a.

20. (Original) A method for identifying compounds which are GDNF analogs

comprising

a) incubating said compounds with cells which express c-RET receptors

under non-permissive conditions for said cells in the presence of amount of GDNF effective

for cell survival; and

b) determining the number of surviving cells as compared with controls

not incubated with said compounds.

Page 5 of 7

Application No.: Not yet available

Preliminary Amendment

21. (Original) The method of claim 20 wherein said cells are selected from the group consisting of PC12, MN-1, and NB2/a.

- 22. (Original) Isolated GDNFR- β comprising the amino acid sequence of SEQ ID NO:2.
- 23. (Original) Isolated GDNFR- β comprising the amino acid sequence of SEQ ID NO:9.
- 24. (Original) A compound comprising the amino acid sequence of SEQ ID NO:2.
- (Original) A compound comprising the amino acid sequence of SEQ ID
 NO:9.
 - 26. (Original) An ioslated nucleic acid having the sequence of SEQ ID No:5.
 - 27. (Original) An ioslated nucleic acid having the sequence of SEQ ID No: 10.
- 28. (New) An isolated receptor that binds glial cell line-derived neurotrophic factor, said receptor comprising a polypeptide having a molecular weight of about 155 kDa, as determined by SDS-PAGE on 4-20% gradient gels and at least one polypeptide having a molecular weight selected from the group consisting of polypeptides of about 55 kDa, 70 kDa, 135 kDa, and 300 kDa molecular weight, as determined by SDS-PAGE on a 4-20% gradient.